Treatment for Intermediate-Stage Hepatocellular Carcinoma: Current Practice and Outcome in Real World Study
), Imelda Maria Loho(2), Cosmas Rinaldi A. Lesmana(3), Rino Alvani Gani(4), Lianda Siregar(5), Agus Sudiro Waspodo(6), Laurentius A Lesmana(7),
(1) Cipto Mangunkusumo National General Hospital, Hepatobiliary Division, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
(2) Dharmais National Cancer Center Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
(3) Cipto Mangunkusumo National General Hospital, Hepatobiliary Division, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
(4) Cipto Mangunkusumo National General Hospital, Hepatobiliary Division, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
(5) Dharmais National Cancer Center Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
(6) Dharmais National Cancer Center Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
(7) Digestive Disease and GI Oncology Centre, Medistra Hospital, University of Indonesia, Jakarta, Indonesia
Corresponding Author
Abstract
Background: Intermediate-stage hepatocellular carcinoma (HCC) is a very heterogeneous disease. The first line treatment for this group is transarterial chemoembolization (TACE), however, in clinical practice, not all patients are suitable for TACE. We aim to evaluate current treatment practice and outcome of patients with intermediate-stage HCC.
Methods: HCC patients database from 2013 to 2016 in Cipto Mangunkusumo Hospital and Dharmais Cancer Hospital were retrospectively analyzed. Patients with intermediate-stage HCC were included in this study.
Results: A total of 456 patients were diagnosed with HCC, but only 151 (33.1%) patients with intermediate-stage HCC were included. Men outnumbered women in a ratio of 3:1. The most common etiology for HCC was hepatitis B virus (HBV) infection, which accounted for 55% of patients. Fifty-two patients (34.4%) were treated with TACE as first-line treatment. Sixty-seven patients (44%) were given best supportive care due to ineligibility for TACE. Frequency of TACE varied from one to eleven times. Overall median survival was 617 days (1.7 years). One-year survival for patients undergoing TACE and liver resection was 47% and 60%, respectively. We did not compare the survival between any treatment groups because the number of patient in each group is not sufficient to be statistically analyzed.
Conclusion: Only 34.4% of patients with intermediate-stage HCC was treated with TACE as first-line treatment. An improvement in the treatment strategy should be done for HCC patients in Indonesia.
Keywords
References
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC Cancer Base no. 112012 6 September 2015. Available from: http://globocan.iarfc.fr/Default.aspx.
Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Seminars in liver disease. 1999;19(3):329-38.
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56.
Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379(9822):1245-55.
Omata M, Lesmana L, Tateishi R, Chen P-J, Lin S-M, Yoshida H, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4(2):439-74.
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908-43.
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182-236.
Lin C-L, Hsieh C-F, Chen T, Lin T-J, Huang T-C, Lee H-C, et al. Risk factors for 1-year mortality in patients with intermediate-stage hepatocellular carcinoma treated solely with transcatheter arterial chemoembolization. Advances in Digestive Medicine. 2014;1(4):126-31.
Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359(9319):1734-9.
Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology (Baltimore, Md). 2002;35(5):1164-71.
Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology (Baltimore, Md). 2003;37(2):429-42.
Kudo M, Han KH, Ye SL, Zhou J, Huang YH, Lin SM, et al. A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements. Liver cancer. 2020;9(3):245-60.
Raoul JL, Sangro B, Forner A, Mazzaferro V, Piscaglia F, Bolondi L, et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer treatment reviews. 2011;37(3):212-20.
Kudo M, Arizumi T, Ueshima K, Sakurai T, Kitano M, Nishida N. Subclassification of BCLC B Stage Hepatocellular Carcinoma and Treatment Strategies: Proposal of Modified Bolondi's Subclassification (Kinki Criteria). Digestive diseases. 2015;33(6):751-8.
Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol. 2012;57(4):821-9.
Zhong JH, Rodriguez AC, Ke Y, Wang YY, Wang L, Li LQ. Hepatic resection as a safe and effective treatment for hepatocellular carcinoma involving a single large tumor, multiple tumors, or macrovascular invasion. Medicine. 2015;94(3):e396.
Tada T, Kumada T, Toyoda H, Tsuji K, Hiraoka A, Itobayashi E, et al. Role of hepatic resection in patients with intermediate-stage hepatocellular carcinoma: A multicenter study from Japan. Cancer science. 2017;108(7):1414-20.
Article Metrics
Abstract View
: 488 times
Download : 359 times
DOI: 10.24871/231202224-28
Refbacks
- There are currently no refbacks.
